Patent Term Extension in Different Jurisdictions
Across patent systems, one feature is common: while the duration of patent protection is fixed by law, the process of examination and grant is administrative and often slow. When this process takes several years, an obvious question arises, should time lost due to state delay be compensated in some way? Jurisdictions have answered this question differently.
United States
The United States addresses patent office delay through Patent Term Adjustment. Section 154(b) of Title 35 of the U.S. Code requires adjustment of the patent term where delays are attributable to the United States Patent and Trademark Office, including delays in commencing examination, delays after allowance, and certain appellate delays.
Patent Term Adjustment operates automatically and follows a statutory formula. It is not linked to the commercial success of the invention or to regulatory approval. The focus is limited to delay caused by the patent office itself.
Courts have clarified the scope of this mechanism. In Wyeth v. Kappos, the U.S. Court of Appeals for the Federal Circuit rejected an interpretation that narrowed adjustment through technical calculations. The Court held that the statute must be applied in a manner that meaningfully accounts for time lost due to agency delay. The decision reflects the U.S. position that defined categories of patent office delay should not be borne entirely by the patentee.
European Union, Japan and South Korea
The European patent system adopts a more restrained approach. There is no mechanism under the European Patent Convention to adjust the patent term for delays in examination or grant. A European patent expires twenty years from the filing date, regardless of how long prosecution takes.
Extension is permitted only in limited circumstances through Supplementary Protection Certificates under Regulation (EC) No 469/2009. These apply mainly to pharmaceutical and plant protection products and are intended to compensate for time lost in obtaining mandatory regulatory approvals, not for delay within the patent office.
Japan and South Korea follow similar models. Article 67(2) of the Japanese Patent Act allows extension where an invention could not be worked due to the time required for regulatory approvals, particularly in pharmaceuticals and agrochemicals. South Korea adopts a comparable approach under Articles 89 to 92 of the Korean Patent Act. In both jurisdictions, extensions are capped, sector-specific, and limited to regulatory delay. Neither provides for adjustment of patent term to compensate for patent office delay.
Taken together, the European Union, Japan, and South Korea reflect a consistent approach: administrative delay in prosecution is not treated as a basis for extending patent duration, while regulatory delay is addressed through narrowly defined statutory mechanisms.
TRIPS Article 33 and the legal basis for adjustment mechanisms
Article 33 of the TRIPS Agreement requires patent protection for a minimum of twenty years from the filing date. The provision sets a floor, not a ceiling. On this basis, jurisdictions that allow patent term adjustment or extension generally argue that such mechanisms do not violate TRIPS, as they are intended to preserve the effective benefit of the minimum term rather than to expand monopoly rights.
Under this framework, adjustment compensates for delay attributable to the State, while extension addresses periods during which the invention could not legally be exploited due to regulatory requirements. While this reasoning is debated, it has generally been treated as consistent with Article 33.
India’s Legislative and Judicial Position
India has adopted a more rigid statutory approach. Section 53 of the Patents Act, 1970 fixes the term of every patent at twenty years from the date of filing and does not provide for any extension or adjustment, whether for administrative or regulatory delay. This reflects India’s decision to implement the TRIPS requirement in a uniform manner.
Indian courts have consistently upheld this position. In Gunjan Sinha @ Kanishk Sinha and Anr. v. Union of India and Ors., the Calcutta High Court rejected claims seeking relief based on delay in the patent grant process. The Court held that patent duration is a matter of legislative policy and that administrative delay does not create a right to alter the statutory term. Any change to patent duration, the Court observed, must come from Parliament.
This approach aligns with broader policy concerns in Indian patent law, including certainty of rights, avoidance of evergreening, and protection of public interest. Delay in examination is treated as an administrative issue to be addressed through procedural reform rather than through modification of substantive patent rights.
The Underlying Policy Tension
At the same time, India’s position highlights an ongoing policy tension. Extended delays in examination can significantly reduce the effective commercial life of a patent, particularly in sectors where post-grant licensing or enforcement is central to value creation. Other jurisdictions address this concern by reallocating the cost of delay through adjustment or limited extension.
India, by contrast, has focused on procedural measures such as expedited examination and administrative streamlining, which seek to mitigate delay without altering the statutory structure of patent rights.
Conclusion
Comparative analysis shows that jurisdictions allocate the consequences of patent grant delay in different ways, shaped by distinct legislative and policy choices. India’s refusal to recognise patent term adjustment or extension places it at one end of this spectrum. While this choice has clear implications for patentees, it reflects a consistent and deliberate policy position within the broader international debate on patent duration and administrative delay.